CJC-1295 vs CJC-1295 DAC
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
A long-acting GHRH analog with Drug Affinity Complex for extended half-life. Provides sustained GH elevation for days with single injection.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | CJC-1295 | CJC-1295 DAC |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. | CJC-1295 DAC contains a reactive linker that binds to albumin after injection. This extends half-life from minutes to 6-8 days, providing sustained GHRH stimulation and GH/IGF-1 elevation. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | Limited community data available See research protocols |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks | 8-12 weeks typical |
| Best Time to Take | Before bed | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg. | Studies show sustained 2-10 fold increase in GH levels lasting several days. Single weekly injection maintains elevated IGF-1. Less physiologic than pulsatile protocols but more convenient. |
Frequently Asked Questions: CJC-1295 vs CJC-1295 DAC
What is the difference between CJC-1295 and CJC-1295 DAC?
CJC-1295 is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. CJC-1295 DAC is a growth hormone peptide that a long-acting ghrh analog with drug affinity complex for extended half-life. provides sustained gh elevation for days with single injection. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 or CJC-1295 DAC?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 is typically used for growth hormone purposes, while CJC-1295 DAC is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 and CJC-1295 DAC be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 and CJC-1295 DAC together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.